Cereno Scientific shares invitation to the Capital Markets Day 2023 on August 30, 2023
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced further information about the company's upcoming Capital Markets Day that will be held on August 30, 2023. We invite analysts, investors, and financial media to join us for insights into our strategy and operations.
The Capital Markets Day will be held on Wednesday, August 30, 2023, starting at 08:30 in central Stockholm. Coffee and refreshments will be served from 08:00. The Capital Markets Day will be held at Haymarket by Scandic, Hötorget 13-15 in Stockholm.
The program will provide an update on Cereno's pipeline, clinical and preclinical development, and growth strategy from both the company as well as external collaborators. A detailed agenda will be provided ahead of time.
Register to attend the event
We hope you can join the Capital Markets Day in-person in Stockholm. Limited seats are available onsite and will be reserved on a first-come-first-served basis.
To attend onsite, please register at: https://financialhearings.com/event/46821
For those not able to join onsite, the Capital Markets Day will be live streamed on Cereno's website and recorded for on-demand viewing. Those who participate online will be able to submit their questions online. The live stream will be available at: https://ir.financialhearings.com/cereno-scientific-cmd-2023
For further information, please contact:
Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.